Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The granule exocytosis pathway is a critical mechanism by which cytotoxic lymphocytes (CTLs and NK cells) induce the death of cancer cells. This process involves the targeted release of lytic granules containing perforin and granzymes at the immunological synapse, leading to pore formation and subsequent apoptosis induction in target cells. FasL/TRAIL can also trigger extrinsic apoptosis. This pathway is essential for anti-tumor immunity, and defects can lead to immunodeficiencies. Therapeutic strategies aim to enhance this pathway through CAR-T/CAR-NK cells and ADCC-based therapies.
Enhancement of granule exocytosis to induce tumor cell lysis.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Granule Exocytosis Pathway in Cancer Cell Lysis.